April 17, 2026
A Manhattan federal judge Friday refused to block Johnson & Johnson from advertising its prostate cancer drug as having a lower risk of death compared with Bayer's medication, saying Bayer has not shown it is likely to succeed on its claims that its rival's advertising campaign is false or misleading.
February 23, 2026
Johnson & Johnson is leaning on a flawed study to advertise its prostate cancer drug as having lower risk of death compared with Bayer's medication, alleged a New York federal lawsuit filed Monday by Bayer, which seeks to immediately halt J&J's advertising campaign and recover damages.